Personalized tamoxifen dosing: can a PET scan show the way?
NCT ID NCT04174352
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This pilot study tests whether a special PET scan (FES-PET/CT) can help doctors find the best dose of tamoxifen for people with metastatic breast cancer that has an ESR1 mutation. These mutations can make standard tamoxifen doses less effective. The study will enroll 12 participants and use the scan to measure how well tamoxifen blocks estrogen receptors at different dose levels. The goal is to identify the optimal dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wisconsin Oncology Network (WONIX) sites
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tamoxifen
What this could lead to
If successful, this could show how to personalize tamoxifen dosing for patients with ESR1 mutations, potentially improving treatment effectiveness.
What could go wrong
This is a very small, early-phase pilot study with only 12 participants. It is designed to find the right dose, not to prove the treatment works, so results may not lead to immediate changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.